Refine by
Patients With Type 2 Diabetes Articles & Analysis: Older
116 news found
This year Protheragen-ING has extended its portfolio of Active Pharmaceutical Ingredients (APIs) to include several hundred new varieties, catering to a broad spectrum of therapeutic needs such as anti-tumor, hypoglycemic, antipsychotic, bronchiectasis, and antihypertensive treatments. Such growth represents Protheragen-ING’s commitment to support researchers worldwide in their quest of ...
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
New subgroup and further analyses of the pivotal studies PULSAR, PHOTON and CANDELA will provide further insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of aflibercept 8 mg versus aflibercept 2 mg (EyleaTM) in patients with neovascular (wet) age-related macular degeneration ...
ByBayer AG
“Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes,” said Dr. ...
ByBayer AG
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute (TGen), part of City of Hope, today announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma (DIPG), a rare and often fatal ...
Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. “Patients with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular event than those with type ...
ByBayer AG
The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a multi-centered, randomized, double-blind, placebo-controlled study that will evaluate the albumin to creatinine ratio in up to 240 adult subjects with type 1 and type 2 diabetes and DKD. ...
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") for ...
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
The Burke research showed that while 52 percent of healthcare providers surveyed agreed patient motivation is a major barrier to adhering to their recommended blood glucose monitoring regimen, only 10 percent of the Type 2 patients agreed that motivation is a major barrier to checking more frequently and 53 percent indicated they ...
ByLifeScan
Aflibercept 8 mg demonstrated non-inferior vision gains to Eylea® (aflibercept 2 mg) with 83% of patients with neovascular (wet) age-related macular degeneration (nAMD) and 93% of patients with diabetic macular edema (DME) maintaining dosing intervals of 12 weeks or longer through week 48 Superior fluid control in nAMD and robust disease control through to week 48 in nAMD and DME In both ...
ByBayer AG
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology ...
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
Avoid thermal damage Fractional carbon dioxide laser treatment can effectively avoid side effects such as thermal damage, and at the same time can promote the healing of the skin, making up for the lack of treatment technology that takes a long time in the recovery period, taking care of the specific requirements of each patient, suitable for all kinds of wrinkles , including ...
The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA DR3-DQ2 haplotype. ...
Diamyd Medical has contributed with study drugs, expertise and some financial support for immunological analyses and determination of HLA haplotypes. About LADA Latent Autoimmune Diabetes in Adults represents close to 10% of patients diagnosed with type 2 diabetes. LADA is characterized by an ongoing autoimmune ...
Finerenone in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use Short Oral Discussion Area 8 September 20, 2022; 1:00 – 2:00pm (CEST) An additional post-hoc analysis from FIDELITY will investigate the effect of Kerendia by baseline HbA1c categories, HbA1c variability, and ...
ByBayer AG
Patients living with chronic kidney disease associated with type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. ...
ByBayer AG
In the September 2022 issue of JACC journals (https://www.jacc.org/doi/10.1016/j.jacc.2022.06.044), the FAVOR III China Study Group published a sub-study that was aimed to ascertain whether the beneficial outcomes of QFR® guidance for lesion selection during PCI is affected by diabetes status. From the total of 3825 patients enrolled, 1295 (33.9%) had diabetes. The study confirmed that the ...